XNAS
TCMD
Market cap498mUSD
Oct 08, Last price
22.12USD
1D
0.45%
1Q
-25.85%
Jan 2017
34.80%
IPO
96.45%
Name
Tactile Systems Technology Inc
Chart & performance
P/E
26.14
P/S
1.51
EPS
0.85
Div yield, %
—
Shrs. gr., 5y
3.78%
Rev. gr., 5y
11.98%
Revenues
330m
+12.47%
Net income
19m
+12.54%
CFO
43m
+5.30%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.
Key people
Peter H. Soderberg
Independent Chairman of the Board · since 2012
Gerald R. Mattys
Chief Executive Officer, Director · since 2005
Brent A. Moen
Chief Financial Officer · since 2018
Robert J. Folkes
Chief Operating Officer · since 2015
Mary M. Thompson
Senior Vice President, Reimbursement and Payer Relations · since 2017
Peter Schaubach
Chief Information Officer · since 2019
Jay Stracke
Vice President of Reimbursement and Payer Relations · since 2019
Bryan F. Rishe
Senior Vice President of Sales · since 2017
William W. Burke
Independent Director · since 2015
Independent Director · since 2012
Independent Director · since 2017
Legal address
C/O COGENCY GLOBAL INC.
850 NEW BURTON ROAD
SUITE 201
DOVER, DE 19904
US
850 NEW BURTON ROAD
SUITE 201
DOVER, DE 19904
US
Headquarters
1331 Tyler Street North East
Suite 200
Minneapolis, MN 55413
US
Suite 200
Minneapolis, MN 55413
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||